NSRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast NSRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSRX is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 6.800

Low

22.00

Averages

22.00

High

22.00

Current: 6.800

Low

22.00

Averages

22.00

High

22.00

Laidlaw

Yale Jen

Buy

initiated

$22

2025-09-29

Reason

Laidlaw

Yale Jen

Price Target

$22

2025-09-29

initiated

Buy

Reason

Laidlaw analyst Yale Jen initiated coverage of Nasus Pharma with a Buy rating and $22 price target. The firm says Nasus is a mid-clinical stage biotech company focusing on the development of NS-002, a "well differentiated" powder-based intranasal anaphylaxis treatment. The "compelling" NS-002 in anaphylaxis Phase II study outcomes bode well for a successful Phase III study and potential approval as the first powder-based intranasal anaphylaxis therapy, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Nasus Pharma Ltd (NSRX.A) is -7.16, compared to its 5-year average forward P/E of -5.36. For a more detailed relative valuation and DCF analysis to assess Nasus Pharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.36

Current PE

-7.16

Overvalued PE

-1.74

Undervalued PE

-8.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.18

Current PS

0.00

Overvalued PS

1.35

Undervalued PS

-0.99

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NSRX News & Events

Events Timeline

No data

News

5.0

11-20Newsfilter

Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO

People Also Watch

Frequently Asked Questions

What is Nasus Pharma Ltd (NSRX) stock price today?

The current price of NSRX is 6.8 USD — it has increased 0 % in the last trading day.

What is Nasus Pharma Ltd (NSRX)'s business?

Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

What is the price predicton of NSRX Stock?

What is Nasus Pharma Ltd (NSRX)'s revenue for the last quarter?

Nasus Pharma Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Nasus Pharma Ltd (NSRX)'s earnings per share (EPS) for the last quarter?

Nasus Pharma Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Nasus Pharma Ltd (NSRX)'s fundamentals?

The market is revising No Change the revenue expectations for NSRX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -16.36%.

How many employees does Nasus Pharma Ltd (NSRX). have?

Nasus Pharma Ltd (NSRX) has 0 emplpoyees as of December 16 2025.

What is Nasus Pharma Ltd (NSRX) market cap?

Today NSRX has the market capitalization of 61.61M USD.